夜間頻尿の世界市場レポート 2025年

夜間頻尿の市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8.0％で42億3,000万米ドルに成長します。予測期間中の成長は、膀胱閉塞障害や尿路炎症の有病率の増加、さまざまな危険因子による夜間頻尿の発症率の上昇、夜間頻尿の一因となる水分摂取量の多さ、睡眠障害や腎臓の健康との関連性に対する意識の高まり、高齢化人口の拡大などに起因すると考えられます。予測期間における主要動向としては、診断法の発展、新薬の開発、夜間頻尿治療に対する研究・投資の増加、外科的・非外科的治療法の進歩、個別化医療の採用などが挙げられます。

心血管疾患の有病率の増加は、夜間頻尿市場の拡大を促進すると予想されています。心血管疾患（CVD）には、心臓病、脳卒中、高血圧など、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。高齢化、座りがちなライフスタイル、不健康な食事、喫煙、過度のアルコール摂取、肥満、高血圧、高コレステロール、糖尿病、遺伝的素因など、いくつかの要因が心血管疾患の発生率増加の一因となっています。夜間頻尿は心血管疾患患者によく見られる症状であり、診断と治療ソリューションに対する需要の高まりにつながっています。高齢化と不健康なライフスタイルにより、心血管疾患は世界的に増加の一途をたどっており、効果的な夜間頻尿管理の必要性は拡大します。例えば、2024年5月、米国の政府機関である疾病対策予防センターは、2022年の米国における死因は心臓病が70万2,880人で、全死亡者の20％を占めると報告しました。毎年、約80万5,000人が心臓発作を起こし、60万5,000人が初発例、20万人が既往歴のある人に発症しています。その結果、心血管疾患の有病率の上昇が夜間頻尿市場の成長を促進しています。

夜間頻尿市場の主要企業は、患者の利便性とコンプライアンスを向上させるため、口腔内崩壊錠などの革新的な治療法の開発に注力しています。口腔内崩壊錠（ODT）は、水を必要とせず口腔内で速やかに溶ける固形剤であり、嚥下困難な患者にとって特に有益です。例えば、2024年7月、マルタに本社を置く製薬会社アダルボ・リミテッドは、中枢性頭蓋糖尿病性不定愁訴などの過剰な水分喪失を引き起こす疾患の治療として、デスモプレシンODTを欧州で発売しました。この合成バソプレッシン錠剤は、天然ホルモンを模倣し、尿中の水分排泄を減少させることにより、糖尿病性不定愁訴、過度の口渇・排尿、おねしょの管理に役立ちます。また、血液凝固因子の放出を促進することにより、軽度から中等度の血友病Aとフォンウィルブランド病の治療に使用されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の夜間頻尿PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の夜間頻尿市場：成長率分析
• 世界の夜間頻尿市場の実績：規模と成長、2019～2024年
• 世界の夜間頻尿市場の予測：規模と成長、2024～2029年、2034年
• 世界の夜間頻尿総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の夜間頻尿市場：薬剤別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗コリン薬
• デスモプレシン
• 抗生物質
• 鎮痙薬
• その他
• 世界の夜間頻尿市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 混合夜間頻尿
• 夜間膀胱容量の低下
• 夜間多尿
• 全身性多尿
• 世界の夜間頻尿市場：原因別、実績と予測、2019～2024年、2024～2029年、2034年
• 泌尿器感染症
• 膀胱腫瘍
• 利尿薬
• 通常のアルコールまたはコーヒー
• 肝臓感染症
• 糖尿病
• 妊娠
• その他の原因
• 世界の夜間頻尿市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 在宅医療
• クリニック
• 世界の夜間頻尿市場、抗コリン薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• オキシブチニン
• トルテロジン
• ソリフェナシン
• ダリフェナシン
• フェソテロジン
• 世界の夜間頻尿市場、デスモプレシンのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 鼻腔内デスモプレシン
• 経口デスモプレシン
• 世界の夜間頻尿市場、抗生物質のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ニトロフラントイン
• トリメトプリム
• ホスホマイシン
• その他の抗生物質
• 世界の夜間頻尿市場、鎮痙薬のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 臭化ブチルスコポラミン
• フラボキサート
• その他の抗けいれん薬
• 世界の夜間頻尿市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アルファ遮断薬
• ベータ3作動薬
• 利尿剤
• その他

第7章 地域別・国別分析

• 世界の夜間頻尿市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の夜間頻尿市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 夜間頻尿市場：競合情勢
• 夜間頻尿市場：企業プロファイル
  • Pfizer Inc
  • Merck & Co. Inc
  • AbbVie Inc
  • Sanofi S.A
  • GlaxoSmithKline plc

第31章 その他の大手企業と革新的企業

• Viatris Inc
• Boehringer Ingelheim International GmbH
• Otsuka Pharmaceutical Co. Ltd
• Astellas Pharma Inc
• Eisai Co. Ltd.
• Sumitomo Dainippon Pharma Co. Ltd
• Ferring Pharmaceuticals A/S
• Avadel Pharmaceuticals plc
• UroGen Pharma Ltd
• Sanwa Kagaku Co. Ltd.
• Urovant Sciences Inc
• Serenity Pharmaceuticals LLC
• Vantia Therapeutics Inc
• AA Pharma Inc
• Wellesley Pharmaceuticals Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 夜間頻尿市場、2029年：新たな機会を提供する国
• 夜間頻尿市場、2029年：新たな機会を提供するセグメント
• 夜間頻尿市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Nocturia is a medical condition characterized by the need to wake up at night one or more times to urinate. It is classified as a lower urinary tract symptom (LUTS) and can stem from various underlying causes, such as excessive fluid intake before bedtime, overactive bladder, urinary tract infections, diabetes, or prostate enlargement in men. Nocturia can significantly affect sleep quality and overall health, leading to fatigue and reduced daytime productivity.

The primary drugs used for nocturia treatment include anticholinergic drugs, desmopressin, antibiotics, antispasmodics, and other medications. Anticholinergic drugs work by blocking acetylcholine to reduce involuntary bladder contractions, helping to manage overactive bladder and nocturia. These medications are indicated for conditions such as mixed nocturia, low nocturnal bladder capacity, nocturnal polyuria, and global polyuria. Nocturia can be caused by factors such as urological infections, bladder tumors, diuretic medications, alcohol or caffeine consumption, liver infections, diabetes, and pregnancy. These treatments are utilized by various end users, including hospitals, home care settings, and clinics.

The nocturia market research report is one of a series of new reports from The Business Research Company that provides nocturia market statistics, including the nocturia industry global market size, regional shares, competitors with the nocturia market share, detailed nocturia market segments, market trends, and opportunities, and any further data you may need to thrive in the nocturia industry. This nocturia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nocturia market size has grown strongly in recent years. It will grow from $2.87 billion in 2024 to $3.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to the increasing prevalence of cardiovascular diseases, a rising incidence of insomnia, an aging population, greater awareness of nocturia and related conditions, and a rise in comorbidities.

The nocturia market size is expected to see strong growth in the next few years. It will grow to $4.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period can be attributed to the increasing prevalence of bladder obstruction disorders and urinary tract inflammation, a rising incidence of nocturia due to various risk factors, high fluid intake contributing to nocturia, growing awareness of its connection to sleep disorders and kidney health, and the expanding aging population. Key trends in the forecast period include advancements in diagnostics, the development of new drugs, increased research and investment in nocturia treatments, progress in both surgical and non-surgical treatment options, and the adoption of personalized medicine.

The increasing prevalence of cardiovascular diseases is expected to drive the expansion of the nocturia market. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including heart disease, stroke, and hypertension. Several factors contribute to the growing incidence of cardiovascular diseases, such as aging populations, sedentary lifestyles, unhealthy diets, smoking, excessive alcohol consumption, obesity, high blood pressure, high cholesterol, diabetes, and genetic predisposition. Nocturia is a common symptom among patients with cardiovascular diseases, leading to increased demand for diagnostic and treatment solutions. As cardiovascular conditions continue to rise globally due to aging and unhealthy lifestyles, the need for effective nocturia management will expand. For example, in May 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that heart disease was responsible for 702,880 deaths in the United States in 2022, accounting for 20% of all fatalities. Each year, approximately 805,000 individuals suffer a heart attack, with 605,000 being first-time cases and 200,000 occurring in those with a prior history. Consequently, the rising prevalence of cardiovascular diseases is fueling the growth of the nocturia market.

Leading companies in the nocturia market are focusing on developing innovative treatments, such as orally disintegrating tablets, to improve patient convenience and compliance. Orally disintegrating tablets (ODTs) are solid dosage forms that dissolve rapidly in the mouth without requiring water, making them particularly beneficial for patients who have difficulty swallowing. For instance, in July 2024, Adalvo Limited, a Malta-based pharmaceutical company, launched Desmopressin ODT in Europe to treat conditions that cause excessive fluid loss, such as central cranial diabetes insipidus. This synthetic vasopressin tablet helps manage diabetes insipidus, excessive thirst and urination, and bedwetting by mimicking the natural hormone and reducing water excretion in urine. Additionally, it is used to treat mild to moderate hemophilia A and von Willebrand disease by promoting the release of blood clotting factors.

In March 2022, Acerus Pharmaceuticals Corporation, a Canada-based biopharmaceutical company, acquired Serenity Pharmaceuticals LLC for an undisclosed amount. This acquisition granted Acerus Pharmaceuticals global rights to Noctiva, strengthening its portfolio in urology and men's health. The deal positions the company for accelerated growth and improved long-term performance. Serenity Pharmaceuticals LLC, a US-based pharmaceutical company, specializes in developing therapies for voiding disorders and urinary health conditions, including nocturia.

Major players in the nocturia market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Sanofi S.A, GlaxoSmithKline plc, Viatris Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd, Astellas Pharma Inc, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd, Ferring Pharmaceuticals A/S, Avadel Pharmaceuticals plc, UroGen Pharma Ltd, Sanwa Kagaku Co. Ltd., Urovant Sciences Inc, Serenity Pharmaceuticals LLC, Vantia Therapeutics Inc, AA Pharma Inc, Wellesley Pharmaceuticals Inc.

North America was the largest region in the nocturia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nocturia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nocturia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nocturia market consists of revenues earned by entities by providing services such as diagnostic services, pharmacological treatment services, behavioral therapy and lifestyle modification services and telemedicine and remote consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nocturia market also includes sales of bladder control devices, alpha-blockers, diuretics, and tricyclic antidepressants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nocturia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nocturia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nocturia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nocturia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Anticholinergic Drugs; Desmopressin; Antibiotics; Antispasmodic; Other Drugs
• 2) By Indication: Mixed Nocturia; Low Nocturnal Bladder Capacity; Nocturnal Polyuria; Global Polyuria
• 3) By Causes: Urological Infection; Tumor Of The bladder; Diuretic Medications; Regular Alcohol Or coffee; Liver infection; Diabetes; Pregnancy; Other Causes
• 4) By End User: Hospitals; Home Care; Clinics
• Subsegments:
• 1) By Anticholinergic Drugs: Oxybutynin; Tolterodine; Solifenacin; Darifenacin; Fesoterodine
• 2) By Desmopressin: Intranasal Desmopressin; Oral Desmopressin
• 3) By Antibiotics: Nitrofurantoin; Trimethoprim; Fosfomycin; Other Antibiotics
• 4) By Antispasmodic: Hyoscine Butylbromide; Flavoxate; Other Antispasmodics
• 5) By Other Drugs: Alpha-blockers; Beta-3 Agonists; Diuretics; Other Pharmacological Treatments
• Companies Mentioned: Pfizer Inc; Merck & Co. Inc; AbbVie Inc; Sanofi S.A; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nocturia Market Characteristics

3. Nocturia Market Trends And Strategies

4. Nocturia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Nocturia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nocturia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nocturia Market Growth Rate Analysis
• 5.4. Global Nocturia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nocturia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nocturia Total Addressable Market (TAM)

6. Nocturia Market Segmentation

• 6.1. Global Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticholinergic Drugs
• Desmopressin
• Antibiotics
• Antispasmodic
• Other Drugs
• 6.2. Global Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mixed Nocturia
• Low Nocturnal Bladder Capacity
• Nocturnal Polyuria
• Global Polyuria
• 6.3. Global Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urological Infection
• Tumor Of The bladder
• Diuretic Medications
• Regular Alcohol Or coffee
• Liver infection
• Diabetes
• Pregnancy
• Other Causes
• 6.4. Global Nocturia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Home Care
• Clinics
• 6.5. Global Nocturia Market, Sub-Segmentation Of Anticholinergic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oxybutynin
• Tolterodine
• Solifenacin
• Darifenacin
• Fesoterodine
• 6.6. Global Nocturia Market, Sub-Segmentation Of Desmopressin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intranasal Desmopressin
• Oral Desmopressin
• 6.7. Global Nocturia Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitrofurantoin
• Trimethoprim
• Fosfomycin
• Other Antibiotics
• 6.8. Global Nocturia Market, Sub-Segmentation Of Antispasmodic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hyoscine Butylbromide
• Flavoxate
• Other Antispasmodics
• 6.9. Global Nocturia Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha-blockers
• Beta-3 Agonists
• Diuretics
• Other Pharmacological Treatments

7. Nocturia Market Regional And Country Analysis

• 7.1. Global Nocturia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nocturia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nocturia Market

• 8.1. Asia-Pacific Nocturia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nocturia Market

• 9.1. China Nocturia Market Overview
• 9.2. China Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nocturia Market

• 10.1. India Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nocturia Market

• 11.1. Japan Nocturia Market Overview
• 11.2. Japan Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nocturia Market

• 12.1. Australia Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nocturia Market

• 13.1. Indonesia Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nocturia Market

• 14.1. South Korea Nocturia Market Overview
• 14.2. South Korea Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nocturia Market

• 15.1. Western Europe Nocturia Market Overview
• 15.2. Western Europe Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nocturia Market

• 16.1. UK Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nocturia Market

• 17.1. Germany Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nocturia Market

• 18.1. France Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nocturia Market

• 19.1. Italy Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nocturia Market

• 20.1. Spain Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nocturia Market

• 21.1. Eastern Europe Nocturia Market Overview
• 21.2. Eastern Europe Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nocturia Market

• 22.1. Russia Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nocturia Market

• 23.1. North America Nocturia Market Overview
• 23.2. North America Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nocturia Market

• 24.1. USA Nocturia Market Overview
• 24.2. USA Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nocturia Market

• 25.1. Canada Nocturia Market Overview
• 25.2. Canada Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nocturia Market

• 26.1. South America Nocturia Market Overview
• 26.2. South America Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nocturia Market

• 27.1. Brazil Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nocturia Market

• 28.1. Middle East Nocturia Market Overview
• 28.2. Middle East Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nocturia Market

• 29.1. Africa Nocturia Market Overview
• 29.2. Africa Nocturia Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nocturia Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nocturia Market, Segmentation By Causes, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nocturia Market Competitive Landscape And Company Profiles

• 30.1. Nocturia Market Competitive Landscape
• 30.2. Nocturia Market Company Profiles
  • 30.2.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Nocturia Market Other Major And Innovative Companies

• 31.1. Viatris Inc
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. Otsuka Pharmaceutical Co. Ltd
• 31.4. Astellas Pharma Inc
• 31.5. Eisai Co. Ltd.
• 31.6. Sumitomo Dainippon Pharma Co. Ltd
• 31.7. Ferring Pharmaceuticals A/S
• 31.8. Avadel Pharmaceuticals plc
• 31.9. UroGen Pharma Ltd
• 31.10. Sanwa Kagaku Co. Ltd.
• 31.11. Urovant Sciences Inc
• 31.12. Serenity Pharmaceuticals LLC
• 31.13. Vantia Therapeutics Inc
• 31.14. AA Pharma Inc
• 31.15. Wellesley Pharmaceuticals Inc

32. Global Nocturia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nocturia Market

34. Recent Developments In The Nocturia Market

35. Nocturia Market High Potential Countries, Segments and Strategies

• 35.1 Nocturia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nocturia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nocturia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer